Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entecavir Consolidation on Post-TDF Treatment Durability
NCT03308890Phase 4Unknown
- Sponsor
- Taipei Veterans General Hospital
- Start
- Nov 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of entecavir in Chronic Hepatitis B (CHB) (3 arms), sponsored by Taipei Veterans General Hospital. Primary endpoint: Clinical relapse rate at 24 months. Status: unknown.
02
Drugs
entecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03308890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308890.